Does OLMESARTAN MEDOXOMIL Cause Cholelithiasis? 264 Reports in FDA Database

Q: Does OLMESARTAN MEDOXOMIL cause Cholelithiasis?

264 reports of Cholelithiasis have been filed with the FDA for OLMESARTAN MEDOXOMIL, representing 2.2% of all OLMESARTAN MEDOXOMIL adverse event reports.

Q: How dangerous is Cholelithiasis from OLMESARTAN MEDOXOMIL?

Of 264 reports, 5 (1.9%) resulted in death and 212 required hospitalization.

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 264 reports of Cholelithiasis have been filed in association with OLMESARTAN MEDOXOMIL (OLMESARTAN MEDOXOMIL). This represents 2.2% of all adverse event reports for OLMESARTAN MEDOXOMIL.

264

Reports of Cholelithiasis with OLMESARTAN MEDOXOMIL

2.2%

of all OLMESARTAN MEDOXOMIL reports

Deaths

212

Hospitalizations

How Dangerous Is Cholelithiasis From OLMESARTAN MEDOXOMIL?

Of the 264 reports, 5 (1.9%) resulted in death, 212 (80.3%) required hospitalization.

Is Cholelithiasis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OLMESARTAN MEDOXOMIL. However, 264 reports have been filed with the FAERS database.

What Other Side Effects Does OLMESARTAN MEDOXOMIL Cause?

Sprue-like enteropathy (3,482) Gastrooesophageal reflux disease (1,819) Acute kidney injury (1,587) Weight decreased (1,569) Haemorrhoids (1,316) Diarrhoea (1,300)